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Emotional Expression During Attention-Deficit/
Hyperactivity Disorders Treatment: 
Initial Assessment of Treatment Effects
C.J. Kratochvil, M.D.,1 D. Faries, Ph.D.,2 B. Vaughan, A.P.R.N.,1 A. Perwien, Ph.D.,2
J. Busner, Ph.D.,3 K. Saylor, Ph.D.,4 S. Kaplan, M.D.,3 C. Buermeyer, Ph.D.,4 and
R. Swindle, Ph.D.2
ABSTRACT
Objective: The purpose of this research was to provide an initial examination of the effects of
atomoxetine and stimulants on emotional expression using a newly developed scale for
assessing emotional expression in children with attention-deficit/hyperactivity disorder
(ADHD). 
Method: The parent-rated Expression and Emotion Scale for Children (EESC) was collected
during two studies. During a cross-sectional validation study, the EESC was completed to assess
the child’s current treatment and retrospectively for previous medication. In a randomized,
placebo-controlled trial of atomoxetine, the EESC was collected at baseline and endpoint. 
Results: In the validation study, no statistically significant differences in EESC scores were
found between groups taking atomoxetine (n 5 74) and stimulants (n 5 105). Patients who
switched from a stimulant to atomoxetine (n 5 40) had greater improvement in emotional
expression than those switched to another stimulant (n 5 21) (p 5 0.008). In the clinical trial,
no difference in rates of worsening of emotional expression were observed (atomoxetine
8.8%, placebo 12.3%; p 5 0.440). 
Conclusion: No treatment differences in emotional expression were observed based on cur-
rent medications. However, stimulant patients needing to switch medications may have
greater improvements in emotional expression by switching to atomoxetine. 
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ALTHOUGH RESEARCH HAS DOCUMENTED the effi-cacy of treatments on the core symptoms
of attention-deficit/hyperactivity disorder
(ADHD) and the common physical side effects
of medications used to treat it (AACAP 2002),
quantitative evaluations of changes in emotional
expression as potential treatment-emergent
effects have been rare. This may be attributed
to a general lack of data on the tolerability of
pediatric pharmacotherapies, or to the lack of
validated instruments for measuring emo-
tional expression. One notable experimental
study demonstrating negative emotional side
effects of stimulant medication is Whalen et al.’s
1University of Nebraska Medical Center, Omaha, Nebraska.
2Eli Lilly & Company, Indianapolis, Indiana.
3PharmaStar, Wayne, Pennsylvania. 
4Neuroscience Inc, Herndon, Virginia.
(1989) cross-over demonstration of observable
“dysphoria” induced by methylphenidate
(MPH). In a pair of blinded placebo-drug cross-
over designs, they used an observer rating
measure in a laboratory group game task. The
rating items comprising the dysphoria rating
measure were “Withdrawn, hanging back,”
“Sad or unhappy,” and “Flat or unemotional.”
In both studies, children on MPH during the
task were rated significantly more dysphoric
than on days when they were on placebo. 
Some clinicians who use medication to treat
ADHD in children have experienced a parent
saying “I don’t want to make my child a zom-
bie.” Clinicians have also seen personality
changes in certain children treated with
ADHD pharmacotherapy. Employing the con-
struct of “negative emotional expression,” in-
cluding affective blunting, mood lability, and
the “zombie effect,” a new parent-reported
scale has been developed in an attempt to
quantify the impact of medication on emo-
tional expression in children: The Expression
and Emotion Scale for Children (EESC).
EESC development
Development of the EESC followed the
guidelines outlined by DeVillis (1991): Defini-
tion and refinement of the construct to be mea-
sured, generation of an item pool, examination
of understandability and appropriateness of
the items and response choices, and determi-
nation of the psychometric properties of the
measure. Qualitative research methods, in-
cluding focus groups and cognitive inter-
views, were used to refine the construct and
develop an initial item pool. On the basis of in-
formation collected from the focus groups, and
the input of clinician investigators with exper-
tise in ADHD, an initial 37-item scale was
developed. Cognitive interviews were then
conducted to examine the understandability
and appropriateness of the items and response
choices on the scale. 
The product of these initial qualitative
phases was the EESC Version 1, a 29-item scale
designed to assess the impact of pharmaco-
therapy on emotional expression in children
treated for ADHD (Kratochvil et al. 2004).
Each item of the EESC is rated on a 5-point
scale (1 5 ‘Not true at all’, 2 5 ‘A little true’, 3
5 ‘Somewhat true’, 4 5 ‘Pretty much true’, 5 5
‘Very much true’). Of the 29 items, 14 ad-
dressed positive aspects of emotional expres-
sion (“My child seems happy.”), with the
remaining 15 concentrating on negative quali-
ties (“My child zones out.”). The scale items
asked parents to rate the child’s mood, emo-
tional state, and personality characteristics
considering the past 2 weeks. For scoring the
EESC, the positive items scores were trans-
formed such that higher scores represent
‘worse’ symptoms for all items and subscales.
Specifically, for positive items, the score ana-
lyzed for each item was ‘6 – raw score’. Total
and subscale scores were then computed as
the sum of the (transformed) item scores. Max-
imum likelihood factor analysis with varimax
orthogonal rotation was used to identify three
potential subscales of the EESC: A 13-item pos-
itive emotions subscale, a 10-item emotional
flatness subscale, and a 5-item emotional lability
subscale.
Details of the development process and a full
assessment of the basic psychometric properties
from the validation study have been docu-
mented in a separate report (Perwien et al.,
submitted). In brief, the validation study con-
firmed that the EESC total score and its sub-
scales have adequate psychometric properties,
although minor modifications to the scale
were recommended (see Appendix). Adequate
internal consistency was observed (Cronbach’s
alpha of 0.91 for the total, 0.87 for positive, 0.90
for flat, 0.86 emotional lability subscales). Con-
vergent and divergent validity were established
using multiple scales and test-retest reliability
was found to range from 0.65 to 0.69 (intraclass
correlation coefficients). The recommended
modifications were to improve the floor effects
of the flat subscale. However, initial testing of
the new items (with improvements in floor
effects) in a subset of patients demonstrated a
high correlation (r 5 0.92) with the original
items. Thus, the analysis here focuses on the full
set of patients with the original items. 
Objectives
The objective of the research presented
here was to employ the EESC for an initial
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examination of the effects of atomoxetine and
stimulants on emotional expression. Data from
both the validation study and a randomized
clinical trial were used. The validation study
includes cross-sectional data from parents of
children with ADHD treated with either atom-
oxetine or a stimulant. This allows for a com-
parison of treatment groups on the basis of
naturalistic selection of treatments. This study
also collected retrospective data from past
treatments, providing an opportunity for pre-
liminary assessment of reported changes in
emotional expression as children change treat-
ments. Data from the randomized, double-
blind clinical trial allowed a prospective
assessment of changes in emotional expression
over time for patients starting treatment with
atomoxetine as compared to placebo. 
METHODS
Validation study
The EESC validation study was conducted at
three experienced ADHD research sites in
Pennsylvania, Maryland, and Nebraska, This
study included 179 parents/guardians (here-
after referred to as parents) and their 6 to 12-
year-old children with ADHD who were taking
either atomoxetine or stimulant medication.
The goals of this study were to examine the
psychometric properties of the scale and make
any necessary modifications. Parents of chil-
dren with a diagnosis of ADHD were recruited
from the community by print advertisements,
letters to community clinicians, and from the
investigators’ own practices. Parents and chil-
dren had to possess an appropriate level of
cognitive skills so that they could communi-
cate suitably with investigators. Per entry crite-
ria, the child’s ADHD must have been
diagnosed by an M.D. or Ph.D. trained in the
assessment of pediatric mental health disor-
ders, and the child must have been on a single
pharmacotherapy treatment for ADHD, either
atomoxetine or a stimulant. The children could
not be on any other concurrent psychotropic
medication. In addition, the current ADHD
treatment must have been stable, that is, no
recent changes in medication or dose of med-
ication for a minimum of 2 weeks. 
Each parent–child dyad attended a single
clinic visit at their participating site. After in-
formed consent was obtained from the parent
and written assent was obtained from the
child, the parent provided demographic and
family information, as well as the child’s med-
ication history, including rationale for prior
medication changes. Parents then completed
the EESC scale for their child on the basis of
his or her current treatment. If the child had
switched medications in the recent past, a ret-
rospective EESC based on the child’s most re-
cent previous ADHD medication was also
completed. A subset of parents completed a
follow-up EESC approximately 2 weeks later
to allow for test–retest reliability assessment.
The computer-based Diagnostic Interview for
Children and Adolescents-IV (DICA-IV; Reich
et al. 1997) was completed by the parent to as-
sess co-morbid disorders. A positive diagnosis
of ADHD based on the DICA-IV was not
required for study participation. Other mea-
sures included the Conners’ Parent Rating
Scale—Revised: short form (CPRS-R:S; Con-
ners 1997), The Child Behavior Checklist
(CBCL; Achenbach 1991; Achenbach and
Rescorla 2001), and the child-rated Child De-
pression Inventory (CDI; Knight et al. 1988; Ko-
vacs 1992), and Multidimensional Anxiety
Scale for Children; (MASC; March et al. 1997)
were also collected at the initial time point. 
Clinical trial
The EESC scale was included as part of a
battery of measurements at 9 of 14 sites in a
randomized, double-blind, atomoxetine clinical
trial. In this trial, 288 (208 from sites where the
EESC was collected) 6 to 12-year-old children
with a Diagnostic and Statistical Manual of
Mental Disorders, 4th edition, text revision
(DSM-IV-TR; American Psychiatric Associa-
tion 2000) diagnosis of ADHD were random-
ized to either atomoxetine morning dosing,
atomoxetine evening dosing, or placebo for
approximately 6 weeks of double-blind treat-
ment. The ADHD diagnosis was established at
study entry using the Kiddie Schedule for Af-
fective Disorders and Schizophrenia for School
Aged Children–Present and Lifetime, Behav-
ioral Disorders Supplement (K-SADS-PL: Beh)
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module criteria for ADHD (Kaufman et al. 1997).
The K-SADS-PL:Beh was administered by a
trained and approved researcher at each site.
Patients were required to score at least 1.5
standard deviations (SD) above the age/gen-
der norm for their ADHD diagnostic subtype
on the ADHD Rating Scale–Parent Version, In-
vestigator Scored (DuPaul 1991; Faries et al.
2001). A medication washout of 5 half-lives
prior to randomization to treatment was re-
quired for children who were taking medica-
tion at the time of study entry. Use of other
psychotropic medications or psychoactive sub-
stances during the course of the study was not
permitted. EESC data were collected at baseline
(randomization visit) and treatment end point
(6 weeks or early discontinuation). Collection of
the EESC data was a secondary objective of the
trial. The primary purpose was to gather data to
assess the relative efficacy and safety of morn-
ing and evening dosing of atomoxetine.
Statistical methods
Analysis of variance (ANOVA) was used to
test the null hypothesis of no group (treat-
ment) differences in EESC scores in both the
validation study and clinical trial data.
ANOVA models for the clinical trial data
analysis included terms for investigational
site, treatment group, and baseline score.
ANOVA models from the validation study in-
cluded investigational site, age, gender, race,
treatment group, co-morbid diagnoses, such as
oppositional defiant disorder (ODD), conduct
disorder (CD), enuresis, encopresis, dys-
thymia, depression, and baseline score (when
change scores were the outcome variable). The
inclusion of additional covariates was impor-
tant in the analyses of the Validation study as
group comparisons from this study are based
on naturalistically selected and not randomly
formed treatment groups. Thus, the covariates
serve as a potential adjustment for selection
bias. As a sensitivity analysis, disease severity
measures (ADHD, depression, anxiety) were
also added to the validation study models as
covariates. The results of the sensitivity analy-
ses were consistent and are not reported here. 
Categorical changes in EESC scores in the
randomized clinical trial were also assessed
using chi-square tests. Changes were catego-
rized based on whether they were less than or
at least 1 standard error of the mean (SEM).
Changes of at least 1 SEM have been previ-
ously utilized as a measure of meaningful
change (Wyrwich et al. 1999). 
Two-sided, 0.05 significance levels were
used for all statistical tests. All statistical analy-
ses were performed using SAS (1999).
RESULTS
Baseline patient characteristics
Tables 1 and 2 summarize the patient char-
acteristics for participants in the validation
study and clinical trial, respectively. Patient
characteristics are provided by current (ongo-
ing) treatment group in the validation study
and by the randomized treatment group in the
clinical trial. The clinical trial population was
less advanced in grade level, with a slightly
higher percentage of males. Differences in
rates of co-morbid diagnoses may be due in
part to the different diagnostic tools–as the
DICA is only used to suggest provisional diag-
noses that would then need examination by a
physician to either confirm or refute the diag-
noses. Overall, the samples appeared to be rea-
sonably representative of the general ADHD
population, predominantly male, combined
subtype, and often presenting with a co-morbid
diagnosis. 
In the randomized clinical trial, the atomox-
etine and placebo treatment groups had simi-
lar patient characteristics. In the validation
study where treatment with atomoxetine or a
stimulant was determined by choice, some dif-
ferences were noted. Specifically, patients tak-
ing atomoxetine tended to be older, less likely
to be Caucasian, more likely to have co-morbid
depression, and had slightly less severe
ADHD symptoms than patients taking stimu-
lants. In addition, the groups had different
treatment histories, with almost two thirds of
the atomoxetine patients having tried a stimu-
lant in the past but only 20% of stimulant
patients having tried atomoxetine in the past.
This discrepancy was likely due to the rela-
tively recent availability of atomoxetine at the
time of the study.
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TABLE 1. SUMMARY OF PATIENT CHARACTERISTICS–VALIDATION STUDY
Atomoxetine Stimulants Test stata p value
n 74 105
Age, mean (SD) 9.8 (1.8) 9.1 (1.8) 2.56 0.011
Grade, mean (SD) 4.6 (1.9) 4.0 (2.0) 2.11 0.037
Male (%) 67.6 65.7 0.07 0.780
Race (% Caucasian) 67.6 81.0 4.19 0.041
Spec education service use (%) 49.3 36.1 2.89 0.089




CPRS ADHD Index, mean (SD) 63.7 (13.3) 67.8 (12.3) 22.10 0.037
MASC Total, mean (SD) 50.4 (9.4) 52.2 (9.4) 21.25 0.207
CDI Total, mean (SD) 49.5 (8.4) 47.6 (9.4) 1.41 0.159
CBCL Total, mean (SD) 59.4 (10.8) 62.3 (10.5) 21.84 0.068
Co-morbid diagnosesb
ODD 44.1 38.4 0.55 0.459
Phobias 19.1 14.1 0.74 0.391
Enuresis 17.7 9.1 2.68 0.101
Conduct disorder 10.3 9.1 0.07 0.795
Major depression 7.4 0.0 7.50 0.006
SD 5 standard deviation; CPRS 5 Conners’ parent rating scale; ADHD 5 attention-deficit/hyperactivity disorder;
MASC 5 multidimensional anxiety scale for children; CDI 5 child depression inventory; CBCL 5 child behavior
checklist; ODD 5 oppositional defiant disorder; DICA-IV 5 diagnostic interview for children and Adolescents-IV; df
5 degrees of freedom.
aTest statistics were t-statistics for continuous measures (with df ranging from 142 for the MASC, 163 for CDI, 175
for CBCL, and 177 for age, grade, and CPRS due to missing data) and chi-square statistics (1 df) for binary variables.
bDiagnosis suggested by DICA-IV.
TABLE 2. SUMMARY OF PATIENT CHARACTERISTICS–CLINICAL TRIAL
Atomoxetine Placebo Test stata p value
n 140 68
Age, mean (SD) 8.8 (1.6) 8.9 (1.7) 20.13 0.900
Grade, mean (SD) 2.9 (1.6) 3.0 (1.7) 20.45 0.656
Male (%) 77.1 73.5 0.33 0.567
Race (% Caucasian) 72.9 70.6 0.12 0.732
Prior stimulant treatment (%) 28.8 41.2 3.20 0.074
ADHD subtype
Hyperactive/Impulsive 2.1 4.4 0.84 0.359
Inattentive 23.6 23.5 0.00 0.995
Mixed 74.3 72.1 0.12 0.732
CGI–Severity 5.1 (0.8) 5.0 (0.7) 0.20 0.809
Co-morbid Diagnosesb
ODD 31.4 38.2 0.95 0.330
Conduct disorder 1.4 0 0.99 0.320
Major depression 0 0 — —
Phobias 0 0 — —
SD 5 standard deviation; ADHD 5 attention-deficit/hyperactivity disorder; CGI-severity 5 Clinical Global
Impressions–severity; ODD 5 oppositional defiant disorder; df 5 degrees of freedom; K-SADS 5 Kiddie Schedule
for Affective Disorders and Schizophrenia for School-Aged Children.
aTest statistics were t statistics for continuous measures (with df of 199 for the CGI to 206 for age and grade) and
chi-square statistics (1df) for binary variables.
bDiagnosis confirmed by K-SADS structured diagnostic interview.
In univariate analyses, EESC scores were not
significantly related to most baseline demo-
graphics and co-morbid diagnoses. Exceptions
in the validation study include higher total
scores for patients with phobias, higher emo-
tional lability scores for females and those
with CD, and higher flat subscale scores for
patients with major depressive disorder
(MDD). Exceptions in the clinical trial in-
cluded higher flat subscale scores for minori-
ties and higher total scores for patients with
oppositional defiant disorder (ODD).
Assessment of treatment effects
Results from three analyses of treatment
differences in EESC scores are presented in the
subsections below: (1) a comparison of EESC
scores between groups formed by naturalisti-
cally selected treatment (atomoxetine vs stimu-
lants) in the validation study; (2) a comparison of
changes in EESC scores from previous to current
treatment for patients in the validation study
who switched from stimulants to atomoxetine
versus patients who switched within the stimu-
lant class of medications; and (3) a comparison of
changes in EESC scores from baseline to end-
point (6 weeks) for atomoxetine-versus placebo-
treated patients in the randomized clinical trial.
Validation study—cross-sectional analysis:
Figure 1 summarizes the mean scores for the
total score and each of the EESC subscales by
the current treatment, atomoxetine or a stimu-
lant. The ‘stimulant’ group was made up of var-
ious treatments, with the most common being
Concerta (43.8%), Adderall (16.2%), Ritalin
(16.2%), and Adderall XR (11.4%). The differ-
ences in scores between patients on atomoxe-
tine [total EESC: mean(SD) 59.3 (17.0)] and on
stimulant (total EESC: mean(SD) 60.5 (16.7))
treatment were small and an ANOVA revealed
no statistically significant differences (F[1,138]
5 0.2, p 5 0.624]. There were also no statistically
significant differences between treatment
groups on the three EESC subscale scores. 
Further analysis showed no significant
differences between short-(most common:
Adderall, Ritalin) and long-acting stimulants
(most common: Concerta, Adderall XR) [long
acting, n 5 60, mean (SD) 5 60.0 (16.8); short
acting, n 5 36, mean (SD) 5 61.2 (16.9); 9 stim-
ulant patients had missing item scores and
were excluded from analyses of total scores].
In addition, the differences between MPH
medications and amphetamine medications
were not statistically significant [MPH: n 5 62,
mean (SD) 5 58.9 (16.9); amphetamine, n 5 30,
mean (SD) 5 63.6 (16.6); p 5 0.165; 4 stimulant
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FIG. 1. EESC mean scores based on current treatment, validation study. Values reports are mean (SD). p Values are
based on F tests from ANOVA with terms for demographics, site, treatment, and co-morbid diagnoses. F statistics
(denominator df) were: Total, 0.2 (138); flat, 0.6 (146); emotion, 1.1 (146); and positive, 0.0 (145). EESC 5 Expression
and emotion scale for children; SD 5 standard deviation; df 5 degrees of freedom; ANOVA 5 analysis of variance.
ATX = atomoxetine; STM = stimulant.
patients were taking modafinil and were
excluded from this analysis].
The overall mean item score, across all items
and treatments, was 2.14 (note: 2 5 ‘a little
true’, 3 5 ‘somewhat true’). Mean item scores
were slightly higher for positively worded
items (2.38) as compared to negatively worded
items (1.94). 
Validation study—retrospective changes: A
total of 87 parents completed both a retrospec-
tive and current EESC scale. The retrospective
scale assessed the child’s most recent previ-
ously used ADHD medication, and thus was
not completed for patients who had not
changed medications. Of the 87 parents with
both scales completed, 44 were parents of
children who had switched from stimulants
(24 short acting, 20 long acting) to atomoxe-
tine. Twenty four records were available for
children switching within the stimulant class:
11 from short to long acting, 7 switching
between long-acting medications, 5 between
short-acting medications, and 1 from long-acting
to a short-acting stimulant. Nineteen parents
provided data about switching from atomoxe-
tine to stimulants.
Table 3 summarizes the changes from past to
current EESC within each medication pattern
group. Significant differences were noted in
mean retrospective EESC total scores, with
higher scores for patients with stimulants as
their past treatment as opposed to patients
with atomoxetine as their past treatment
(F[1,46] 5 6.7, p 5 0.013). All groups (those
switching from stimulants and those switch-
ing from atomoxetine) improved upon the
switch of medications, with larger improve-
ments from patients switching from stimu-
lants. Those on stimulants in the past (whether
switching to atomoxetine or another stimu-
lant) also had significant improvements using
each of the three EESC subscales. 
Figure 2 presents the analysis of changes
from retrospective to current EESC scores
(total and subscales) for patients switching
from stimulants to atomoxetine versus pa-
tients switching from a stimulant to a different
stimulant. These two groups were compared
statistically because they had the largest
sample sizes and similar retrospective scores.
Patients switching from stimulants to atomox-
etine had significantly greater improvements
in emotional expression compared to those
switching within the stimulant class (F[1,31]
5 8.1, p 5 0.008). Whereas those switching to
atomoxetine were found to have numerically
greater improvements on all three EESC sub-
scales, the difference was driven primarily by
improvements in the Emotional Flatness sub-
scale (F 5 13.8[1,33], p 5 0.001).
Clinical Trial—changes for atomoxetine- and
placebo-treated patients: In the double-blind
clinical trial, 136 patients randomized to ato-
moxetine and 65 patients randomized to
placebo had both a baseline and post-baseline
EESC scale completed. Table 4 presents the
summary statistics on baseline and change
scores for the EESC total as well as results of
the ANOVA assessment of differences be-
tween the atomoxetine and placebo groups.
Within-group mean changes over the 6-week
trial indicated small but statistically signifi-
cant improvements for both atomoxetine and
placebo-treated patients. The analysis of treat-
ment differences did not detect any statisti-
cally significant differences in change scores
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TABLE 3. CHANGES FROM PAST TO CURRENT TREATMENT EESC TOTAL SCORES–WITHIN GROUP CHANGES: VALIDATION STUDY
Change: 
Prior Prior to current Within-group
Past and Current Treatment n mean (SD) mean (SD) Test-statistic p value
Atomoxetine to Stimulant 18 67.4 (17.9) 26.2 (15.1) 21.75 0.099
Stimulant to Atomoxetine 40 83.4 (24.2) 221.6 (29.1) 24.69 ,0.001
Stimulant to Stimulant 21 81.9 (21.5) 215.1 (18.5) 23.75 0.001
All subscales also demonstrated significant improvement from the prior score. Test statistics/p values were based
on paired t-tests. EESC scales for 8 patients were not fully completed and not included in this analysis. 
SD 5 standard deviation.
between the atomoxetine and placebo groups
for the EESC total (F[1,190] 5 0.01, p 5 0.923)
and subscale scores. 
In addition to evaluating mean changes, pa-
tients were also classified on the basis of their
changes relative to the SEM. This was done to
identify if there were subsets of patients in
either treatment group for whom emotional
expression changes were potentially problem-
atic and that may be missed in a mean change
analysis. The percentages of patients with im-
provements of more than 1 SEM, no change
(improvement or worsening of , 1 SEM), and
worsening of at least 1 SEM were computed
for each treatment group. Table 5 summa-
rizes these results. Once again, incidences of
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FIG. 2. Changes from retrospective to current EESC scores, validation study. Values reported are mean (SD).
STM_ATX–patients switched from a stimulant to atomoxetine; STM_STM 5 patients switched from a stimulant to
another stimulant. p Values are based on F tests from ANOVA with terms for demographics, site, treatment, retro-
spective score, and co-morbid diagnoses. F statistics (denominator df) were: Total, 8.1 (31); flat, 13.8 (33); emotion, 1.1
(36); and positive, 2.5 (32). EESC 5 Expression and Emotion scale for children; SD 5 standard deviation; ANOVA 5
analysis of variance.
TABLE 4. CHANGES FROM BASELINE TO END POINT IN EESC TOTAL SCORE: CLINICAL TRIAL.
Baseline End point Change F statistic p value vs
Treatment n mean (SD) mean (SD) Mean (SD) (denom df) placebo
Total score
Atomoxetine 136 63.6 (18.3) 60.4 (18.5) 23.1 (14.6) 0.01 (190) 0.923
Placebo 65 68.2 (20.2) 63.6 (19.5) 24.6 (15.5) —
Positive emotions
Atomoxetine 139 31.4 (10.3) 31.2 (10.0) 20.2 (8.3) 0.00 (193) 0.973
Placebo 65 34.0 (10.9) 32.9 (10.4) 21.2 (7.8) —
Emotional flatness
Atomoxetine 137 17.7 (6.7) 16.5 (7.1) 21.2 (6.0) 0.40 (192) 0.528
Placebo 66 18.5 (9.0) 16.3 (7.3) 22.1 (7.3) —
Emotional lability
Atomoxetine 138 14.6 (5.5) 12.7 (5.1) 21.9 (4.4) 1.59 (195) 0.209
Placebo 68 15.7 (4.8) 14.1 (5.3) 21.6 (3.6) —
EESC 5 Expression and Emotion scale for children; SD 5 Standard deviation; df 5 degrees of freedom; ANOVA 5
analysis of variance. 
p values based on F tests from an ANOVA model on change from baseline to end-point scores with terms for base-
line score, site, and treatment. Sample sizes vary across measures due to missing item scores.
worsening between the groups were similar,
and there were no statistically significance dif-
ferences in any of the categories. 
DISCUSSION
The EESC is potentially a useful clinical tool
for assessing changes in emotional and per-
sonality expression in children treated with
pharmacotherapy for ADHD. It goes beyond
the traditional focus on monitoring core symp-
toms of ADHD or commonly reported adverse
effects, such as changes in appetite or sleep.
Previous work has suggested that the EESC is
a reliable and valid tool with three factors:
Positive emotional expression, emotional flat-
ness, and emotional lability. This analysis pro-
vided the initial use of the EESC to assess
medication group differences. 
Three main findings regarding treatment
effects were suggested by the data. First, for
patients on stable treatment with their natural-
istically selected medication (suggesting that
the medication was at least reasonably toler-
ated and effective), no treatment differences in
emotional expression were observed. This
finding included comparisons between atom-
oxetine and stimulants and between differ-
ent types of stimulants. Second, the large
improvements from the retrospective to cur-
rent EESC scores for patients changing med-
ications suggest that emotional expression
may be improved in those patients experiencing
adverse emotional effects by selecting an alter-
native medication. Patients who switched from
stimulant treatments had greater improve-
ments in emotional expression by switching
to atomoxetine than to another stimulant.
Third, the randomized double-blind placebo-
controlled study suggested that atomoxetine
treatment did not dramatically improve emo-
tional expression, nor did it negatively affect
emotional expression in children.
Limitations to this work include the nonran-
domized nature of the treatment comparisons
from the validation study and the reliance
upon retrospective data to produce EESC
scores on past medication treatment. Potential
biases from using recall data include the possi-
bility for scores to be influenced by the current
state of the parent, knowledge of resolution of
problems, and emphasis on salient events over
representative events (Gorin and Stone 2001;
Henker et al 2002). Given that no prospective
differences were found in responsiveness
using atomoxetine or placebo, there as yet is
no data prospectively demonstrating differen-
tial responsiveness to change on the EESC.
Thus, it is not absolutely clear whether atom-
oxetine has no effects on emotional respon-
siveness, or if EESC will be sensitive in
detecting changes in the kind of dysphoria
demonstrated by Whalen et al. (1989) with
MPH. Additionally, there is no placebo-
controlled data yet available using the EESC
on stimulant treatment, or blinded comparator
studies. These data would be of interest to
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TABLE 5. ANALYSIS OF CATEGORICAL CHANGES IN EESC SCORES BY TREATMENT GROUP: CLINICAL TRIAL
Atomoxetine Placebo
(n 5 136) (n 5 65)
categorical changea (%) categorical changea (%)
Increase Same Decrease Increase Same Decrease statistic p value
Total score 8.8 62.5 28.7 12.3 63.1 24.6 0.80 0.669
Subscales
Positive 13.7 67.6 18.7 12.3 64.6 23.1 0.54 0.762
Flat 8.8 64.2 27.0 10.6 68.2 21.2 0.86 0.649
Emotional 13.8 44.9 41.3 8.8 57.4 33.8 3.01 0.222
EESC 5 Expression and Emotion scale for children; SEM 5 standard error of measurement; df 5 degrees of freedom.
aIncrease represents an increase (worsening) in scores of at least one SEM. Decrease represents improvement of at
least 1 SEM. Same represents absolute changes of less than 1 SEM. The SEM was determined by test–retest reliability
data for each subscale. Treatment differences in percentages were assessed using chi-square tests with 2 df.
Chi-square
randomized patients needing to switch medica-
tions and to assess changes on the new medica-
tions. More data on responsiveness of the scale
and a greater understanding of the clinical
meaning of changes of various magnitudes also
will be valuable. Last, minor modifications to the
scale have been suggested and additional data
using the modified version should be collected.
Because this study represents the first look
at medication differences with the EESC, repli-
cation and extension to other child clinical and
nonclinical samples is needed. However, the
information gathered thus far indicates that
the EESC has the potential to provide clinically
valuable information regarding medication
effects on emotional expression in children
with ADHD.
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APPENDIX
EESC Version 1
Read each statement carefully and mark your response based on when your child is on his/her
current ADHD medication. Think about the past two weeks. There are no right or wrong answers.
Not at all A little Somewhat Pretty much Very much
On ADHD medication … true true true true true
1. My child does not talk enough 1 2 3 4 5
2. My child’s mood is flat 1 2 3 4 5
3. My child has sparkle in his/her personality 1 2 3 4 5
4. My child seems happy 1 2 3 4 5
5. My child gets upset easily 1 2 3 4 5
6. My child seems easy going 1 2 3 4 5
7. My child’s personality has blossomed 1 2 3 4 5
8. My child’s personality seems “dampened” 1 2 3 4 5
9. My child is outgoing 1 2 3 4 5
10. My child seems down 1 2 3 4 5
11. My child just doesn’t seem to be him/herself 1 2 3 4 5
12. My child stays to him/herself 1 2 3 4 5
13. My child is tearful 1 2 3 4 5
14. My child’s true personality comes through 1 2 3 4 5
15. My child is sluggish 1 2 3 4 5
16. My child zones out 1 2 3 4 5
17. My child lacks his/her spark 1 2 3 4 5
18. My child is irritable or cranky 1 2 3 4 5
19. My child shows a range of emotions 1 2 3 4 5
20. My child is enthusiastic towards life 1 2 3 4 5
21. My child is friendly 1 2 3 4 5
22. My child’s emotions seem flat 1 2 3 4 5
23. My child has mood swings 1 2 3 4 5
24. My child is spontaneous 1 2 3 4 5
25. My child is overly sensitive 1 2 3 4 5
26. My child is affectionate 1 2 3 4 5
27. My child is funny 1 2 3 4 5
28. My child is creative 1 2 3 4 5
29. My child is confident 1 2 3 4 5
Positive Subscale: items 3, 4, 6, 7, 9, 14, 20, 21, 24, 26, 27, 28, and 29. 
Flat Subscale: items 1, 2, 8, 10, 11, 12, 15, 16, 17, and 22. 
Emotional Lability Subscale: items 5, 13, 18, 23, and 25. 
Note: The following revisions were proposed for Version 2.0 (Perwien et al., submitted):
The following items are deleted: items 19, 1, 2, 8, 10, 12, 15, 17, 22.
The following items are added: My child seems “blah” sometimes; My child isn't very social sometimes; My child
doesn't have much spunk sometimes; My child could care less what happens at times; My child seems too slowed
down sometimes; My child seems somewhat distant at times; My child looks somewhat zoned out at times; My
child's emotions appear a little flat at times.
Copyright © 2006 Eli Lilly and Company and University of Nebraska
For permission to use the scale free of charge, please contact Dr. Chris Kratochvil, Psychopharmacology Research
Center, University of Nebraska Medical Center: ckratoch@unmc.edu 

